ASCO Annual Meeting | Conference

ASCO 2025: Top Data Highlights from 6/2

June 3rd 2025

MedNews Week hosts speak with 8 key opinion leaders at ASCO 2025 about the top data highlights of the day.

Dellphi-304 Data Reinforce Role of Tarlatamab as Second-Line SOC in Small Cell Lung Cancer

June 3rd 2025

Tarlatamab improved overall survival and progression-free survival in the second-line treatment of small cell lung cancer.

Neoadjuvant Osimertinib Yields MPRs With or Without Chemotherapy in Resectable EGFR-Mutated NSCLC

June 3rd 2025

Neoadjuvant osimertinib as monotherapy or plus chemotherapy was more effective vs chemotherapy alone in patients with resectable EGFR-mutated NSCLC.

Lifileucel Sustains Long-Term Responses and Survival in Advanced Melanoma

June 2nd 2025

Second-line lifileucel generated durable responses and survival signals in patients with advanced melanoma, according to a 5-year analysis.

Dr In on the Safety and Efficacy of RP1 in Patients With Melanoma Post–PD-1 Inhibitor Progression

June 2nd 2025

Gino Kim In, MD, shares findings from a subgroup analysis of RP1 efficacy in injected and non-injected melanoma lesions after PD-1 inhibitor progression.

Dr Tolaney on the PFS Benefit With First-Line T-DXd Plus Pertuzumab in HER2+ Breast Cancer

June 2nd 2025

Sara M. Tolaney, MD, MPH, shares interim efficacy results from the DESTINY-Breast09 study of first-line T-DXd plus pertuzumab in HER2-positive breast cancer.

COCOON DM Regimen Reduces Amivantamab/Lazertinib Effects on QOL in EGFR-Mutated NSCLC

June 2nd 2025

COCOON DM reduced the severity and QOL influence of dermatologic AEs vs SOC DM in EGFR-mutant, advanced NSCLC treated with amivantamab plus lazertinib.

Dr Olawaiye on Data for Relacorilant Plus Nab-Paclitaxel in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Alexander Olawaiye, MD, discusses the efficacy and safety of relacorilant plus nab-Paclitaxel in platinum-resistant ovarian cancer.

D-VRd Retains Its Role as a Standard of Care for Transplant-Ineligible Multiple Myeloma

June 2nd 2025

D-VRd led to deeper and more durable responses that translated into improved PFS vs VRd alone in transplant-ineligible patients with multiple myeloma.

Dr Duska on the Role of Immunotherapy With Definitive Treatment in High-Risk, Locally Advanced Cervical Cancer

June 2nd 2025

Linda R. Duska, MD, MPH, on incorporating immunotherapy into definitive therapy for high-risk, locally advanced cervical cancer.

Frontline Disitamab Vedotin Yields Responses in Gastric/GEJ Cancer With Various HER2 Expression Levels

June 2nd 2025

The addition of disitamab vedotin to toripalimab and trastuzumab and/or CAPOX led to favorable response rates in HER2-expressing gastric/GEJ cancer.

Relacorilant Combo Improves PFS, Trends Toward Superior OS in Platinum-Resistant Ovarian Cancer

June 2nd 2025

Relacorilant plus nab-paclitaxel showed meaningful PFS and OS gains, offering a potential new option for patients with platinum-resistant ovarian cancer.

Dostarlimab Plus Chemo With Maintenance Niraparib Generates Modest PFS Boost in Advanced Ovarian Cancer

June 2nd 2025

Dostarlimab/chemotherapy plus maintenance niraparib showed clinically modest PFS improvements vs niraparib alone in newly diagnosed advanced ovarian cancer.

Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer

June 2nd 2025

Erika Hamilton, MD, discusses data for vepdegestrant vs fulvestrant in ER-positive, HER2-negative advanced breast cancer.

KEYNOTE-A18 Data Support Pembrolizumab Plus CCRT as New SOC in High-Risk Cervical Cancer

June 2nd 2025

Pembrolizumab plus CCRT showcases sustained survival benefits in high-risk locally advanced cervical cancer.

Perioperative Nivolumab Sustains EFS Advantage in Resectable NSCLC, With Enriched Benefit in ctDNA–, pCR Responders

June 2nd 2025

Neoadjuvant chemotherapy and nivolumab and adjuvant nivolumab prolonged EFS vs placebo in patients with resectable NSCLC in follow-up from CheckMate-77T.

Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer

June 2nd 2025

Patients with metastatic breast cancer with higher HER2 amplicon mRNA signatures prior to T-DXd therapy had better outcomes vs those with lower signatures.

Cabozantinib Displays Activity as Combination Component and Monotherapy in Second-Line Advanced RCC

June 2nd 2025

Cabozantinib plus atezolizumab or cabozantinib alone was effective regardless of prior immunotherapy or TKI treatment in second-line advanced RCC.

LB2102 CAR T-Cell Therapy Is Well Tolerated, Yields Disease Control in R/R SCLC and LCNEC

June 2nd 2025

The DLL3-directed CAR T-cell therapy LB2102 was safe with preliminary antitumor activity in small cell lung cancer and large cell neuroendocrine carcinoma.

Dr Sammons on the Efficacy of RLY-2608 Plus Fulvestrant in PIK3CA-Mutant HR+/HER2– Breast Cancer

June 2nd 2025

Sarah Sammons, MD, discusses early efficacy data with RLY-2608 plus fulvestrant in PIK3CA-mutant, hormone receptor–positive, HER2-negative breast cancer.